Selective removal of pathogenic proteins
PrimaryOrigami Therapeutics' central causal theory is that neurodegenerative diseases are driven in part by disease-related protein species, and that selectively degrading those pathogenic forms while sparing normal protein forms should reduce toxic proteopathy and slow disease progression. This is framed as disease-modifying rather than symptomatic because the intervention targets an upstream molecular cause of neuronal dysfunction. Testable predictions include reduced levels of disease-associated protein species in treated cells or models, preservation of normal protein function, improved neuronal survival or function, and delayed or reduced clinical progression in disorders such as Huntington's disease, Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia.
Popperian evaluation
The starting biology is credible: pathogenic protein species are central features of several neurodegenerative diseases, and tau aggregates are defining lesions in tauopathies. The weaker step is causality. The dossier states the key assumption plainly: these species must be toxic drivers, not only downstream markers. That is plausible, but it is not settled across Huntington's disease, Alzheimer's disease, Parkinson's disease, ALS, and frontotemporal dementia as one broad class.
Supporting evidence: The evidence context rates the premise that neurodegenerative diseases are driven in part by disease-related pathogenic protein species as high confidence.; The cited 2024 tauopathy framework describes pathological tau aggregates as defining features of tauopathies.; Origami's stated program targets selective degradation of pathogenic protein forms, which follows directly from the proposed disease mechanism.
Counter evidence: The dossier itself labels the causal toxicity claim as a medium-confidence assumption.; Protein aggregates can be disease markers, compensatory deposits, or late-stage debris in some contexts; the supplied evidence does not prove they are the dominant driver in each named disorder.; No direct Origami-specific preclinical or clinical efficacy data are included here.
The theory explains why reducing disease-associated protein species could improve neuronal survival and function: fewer toxic species should mean less proteopathy. It also explains why target engagement biomarkers matter. But it does not yet beat alternative explanations strongly. Neurodegeneration can involve proteostasis failure, inflammation, mitochondrial stress, lysosomal dysfunction, RNA toxicity, and circuit-level degeneration. Protein removal may be one useful handle, but the evidence provided does not show it is the main causal handle.
Supporting evidence: The reasoning chain links pathogenic protein species to toxic proteopathy, neuronal dysfunction, and expected disease modification.; The tauopathy translation framework emphasizes target engagement and surrogate disease biomarkers, which fits a protein-clearance theory.; Predictions include reduced pathogenic protein species, preserved normal protein function, improved neuronal survival, and slower clinical progression.
Counter evidence: The strongest publication support is a translational framework for tauopathies, not proof that selective degradation changes disease course.; The theory spans several biologically different disorders, which weakens explanatory precision unless each disease has its own pathogenic species, assay, and causal validation.; The supplied evidence does not compare this theory against other mechanisms such as neuroinflammation, impaired autophagy, or mitochondrial dysfunction.
This is testable in a clean Popperian sense. A degrader should lower disease-associated protein species, spare normal protein function, improve neuronal phenotypes in models, and slow clinical progression in patients. Failure at any of those levels would damage the theory. The strongest falsifier would be selective target engagement without neuronal or clinical benefit: that would say the protein species was removable, but not causal enough to matter.
Supporting evidence: The theory predicts reduced levels of disease-associated protein species in treated cells or models.; It predicts preservation of normal protein function despite removal of pathogenic forms.; It predicts improved neuronal survival or function and delayed or reduced clinical progression in named neurodegenerative diseases.
Counter evidence: Clinical progression in neurodegenerative disease is slow and noisy, so late-stage falsification may take years.; The theory needs disease-specific definitions of pathogenic species and normal function; without those, negative results can be blamed on the wrong assay or wrong patient group.; No threshold is supplied for how much pathogenic protein reduction should be enough to count as target engagement.
Reasoning tree
Public endorsements
Beth Hoffman publicly backs the theory. She says she is "a fan of going to the root of the problem to solve it," and multiple public event and interview records place her discussing Origami's CNS protein degrader approach and targeting disease-causing proteins in neurodegeneration. That is not vague adjacency. It is a direct public defense of degrading pathogenic proteins as a disease-modifying strategy.
Evidence publication IDs: a3c72e03-73b3-4054-8a1d-f91c4e1901bf, 1aed4f63-9044-413c-b131-815678459993
Eli Lilly appears in the evidence only in unrelated items about CNS hiring, executive trading chatter, asset deals, and metabolic disease positioning. The Origami Therapeutics records describe Origami's protein degradation platform, but none tie Eli Lilly to that theory or show Lilly endorsing, mentioning, or disputing selective removal of pathogenic proteins.
Beth Hoffman is Origami's founder and CEO, and the public records repeatedly describe her explaining or discussing protein degraders as a way to target disease-causing proteins in neurodegenerative disease. The May 1, 2026 video says she explains how the approach works and why it holds promise, the September 1, 2024 interview says Origami uses protein degraders against neurodegenerative targets, and the March 16, 2022 podcast is explicitly about using protein degraders to treat these diseases. That is public endorsement, even though we do not have verbatim quotes here.
Evidence publication IDs: a3c72e03-73b3-4054-8a1d-f91c4e1901bf, 1aed4f63-9044-413c-b131-815678459993, 59dfe989-5b36-4885-b83e-e2358cff5bd2
The record shows Leslie Schulze is Origami Therapeutics' co-founder and CFO, and Origami publicly describes a protein degradation platform aimed at disease modification in neurodegeneration. But the evidence provided does not show Schulze herself making a public statement about selectively degrading pathogenic protein species, so we cannot credit her with an endorsement or contradiction.